The cannabis sector is relatively broad, spanning FDA-approved drugs to consumer products. Both markets are still at a fraction of their potential peak sizes due to laws forbidding the use of cannabis and also regulatory hesitance to approve drugs with related active ingredients. Worldwide sales for all regulator-approved cannabinoid therapeutics were only $53m in 2018 while the total legal cannabis market in the United States was only around $8bn in 2017 compared to $234bn in sales for the a
02 May 2019
Cannabis - Where are we and where are we going?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Cannabis - Where are we and where are we going?
Insys Therapeutics Inc (INSYQ:NYSE), 0 | Eli Lilly and Company (0Q1G:LON), 0 | Corbus Pharmaceuticals Holdings Inc (0SZI:LON), 0 | Johnson & Johnson (0R34:LON), 14,560
- Published:
02 May 2019 -
Author:
Maxim Jacobs -
Pages:
19
The cannabis sector is relatively broad, spanning FDA-approved drugs to consumer products. Both markets are still at a fraction of their potential peak sizes due to laws forbidding the use of cannabis and also regulatory hesitance to approve drugs with related active ingredients. Worldwide sales for all regulator-approved cannabinoid therapeutics were only $53m in 2018 while the total legal cannabis market in the United States was only around $8bn in 2017 compared to $234bn in sales for the a